Osang Healthcare

Osang Healthcare develops advanced medical devices and innovative healthcare solutions in South Korea.

Osang Healthcare Co., Ltd reports a **KRW 2.76 million** revenue decline in Q2 2026, down from **KRW 3.67 million** in the same period last year. The company also widens its net loss to **KRW 4,268.63 million**, up from **KRW 243.44 million** year-over-year. Basic and diluted loss per share from continuing operations both rise to **KRW 310**, compared to **KRW 18** in 2025.

Aug 2026MarketScreenerNews article

Sewon Co., Ltd and Polaris AI Corp acquired a **36.8% stake in HANDYSOFT, Inc** from Osang Healthcare Co., Ltd, Osang Co., Ltd, and individual shareholders for **KRW 50 billion**. The deal includes a cash payment of **KRW 7,000 per share**, finalized on **July 21, 2025**. Before the acquisition, Osang Healthcare Co., Ltd held **25.03%**, Osang Co., Ltd held **15.92%**, and Lee Dong-hyun held **4%** of HANDYSOFT’s shares.

Sep 2025MarketScreenerNews article

OSANG Healthcare achieves a 4.1 billion won operating profit in Q1 2025, marking its first profitable quarter. The company’s consolidated revenue rises 55% year-over-year to 32.1 billion won, driven by a newly launched product. This shift reflects improved financial performance following last quarter’s losses.

May 2025CHOSUNBIZNews article

Osang Healthcare receives FDA clearance for rapid antigen tests detecting SARS-CoV-2, influenza A, and influenza B. The tests deliver results in **15 minutes**, enabling faster diagnosis of concurrent respiratory infections. The approval expands access to combined screening tools amid ongoing seasonal virus risks.

Jan 2025genomeweb.comNews article